Sino Biopharmaceutical stock
Price history
−27.38% over the period1 year: from $7.03 (November 20, 2025) to $5.11 (November 20, 2026), −27.38%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $5.11 |
| October 30, 2026 | $4.82 |
| September 30, 2026 | $5.71 |
| August 31, 2026 | $5.45 |
| July 31, 2026 | $5.03 |
| June 30, 2026 | $4.41 |
| May 29, 2026 | $4.99 |
| April 30, 2026 | $5.42 |
| March 31, 2026 | $5.89 |
| February 27, 2026 | $6.05 |
| January 30, 2026 | $6.64 |
| December 31, 2025 | $6.18 |
| November 28, 2025 | $7.05 |
| November 20, 2025 | $7.03 |
At a glance
The company
Chinese biopharmaceutical company developing and commercializing oncology, liver disease, respiratory and surgery/analgesia medicines
Latest results
Quarter to June 30, 2026 · EPS ¥0.19
Next event
TickerLandia's take on Sino Biopharmaceutical
- Priced in line with similar companies: trailing 12-month P/E 34 vs 37 (−7%) in a group of 8.
- Strong point: Earnings stability (91/100 in its group). Weak point: Financial strength (33/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−30.07% from the 52-week high
Analysts · 23 analysts
Average target$8.49+66.23% vs. price
Buy 21 · Hold 2 · Sell 0 · Strong buy
TickerLandia Fingerprint: Sino Biopharmaceutical
Compared with similar companies: very high earnings stability and very high dividend.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricelow22
How much it costs relative to what it produces.
Metric Value Position in group Price/book 2.39 13 Price/sales 2.71 10 P/E (trailing 12 months) 34.2 47 EV/EBITDA 9.48 12 Forward P/E 15.8 28 Profitabilityaverage59
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 28.2% 68 ROE 14.1% 57 ROA 7.5% 61 Gross margin 82.4% 63 Net margin 7.1% 45 Earnings stabilityvery high91
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.4% 97 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthlow35
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +1.50% 53 Revenue growth (year over year) +10.60% 30 Average revenue growth (3 years) +6.95% 22 Financial strengthlow33
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.63 12 Interest coverage 22.6 62 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.54 25 Debt/equitycounts in reverse: lower means more financial strength 0.37 31 Dividendvery high86
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 2.7% 92 Payout ratio 80.0% 86 Consecutive dividend years 23 years 80 Market momentumaverage50
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +8.61% 63 Relative strength (6 months) +13.02% 71 1-year return −27.38% 15 Distance from 200-day average −6.42% 52 Riskhigh66
How much the price swings.
Metric Value Position in group Beta (1 year) 1.13 71 Maximum drawdown (12 months) 40.1% 59 Volatility (60 days) 47.6% 68
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Sino Biopharmaceutical is cheaper than similar companies
Sino Biopharmaceutical's P/E (trailing 12 months): 34.2, −7% against the median of a group of 8 similar companies (36.8).
Compared with 8 similar companies
| Metric | Sino Biopharmaceutical | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 34.2 | Middle | |
| Forward P/E | 15.8 | Low | |
| Operating margin | 28.2% | Middle | |
| ROE | 14.1% | Middle | |
| Debt/equity | 0.37 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Sino Biopharmaceutical. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥19.44B
Latest quarter · Q2 2026
Net income
¥3.43B
Latest quarter · Q2 2026
Quarterly net margin
17.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $91.32B
- P/E
- 34.2
- EPS
- $0.15
- Volume
- 10.85M
- Daily trading
- €46.07M
- Dividend yield
- 2.35%
- Last ex-dividend on September 1, 2026
How Sino Biopharmaceutical is changing
All resultsRevenue grew 6.1% a year on average over the last 5 years
Shares outstanding down 4.0% in 5 years
Revenue has grown for 3 fiscal years in a row
Returns
Sino Biopharmaceutical returns with dividends
$1,000 invested in Sino Biopharmaceutical 5 years ago, on November 22, 2021, would be worth $990 today with dividends reinvested: −1.02% in total, −0.20% per year. On price alone it would be $889 (−11.06%).
| Period | Sino Biopharmaceutical | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −5.46% | −6.10% | $945 |
| 6 months | −1.26% | −12.63% | $987 |
| Year to date | −17.39% | −12.56% | $826 |
| 1 year | −25.58% | −13.26% | $744 |
| 3 years | +41.73% | +26.06% | $1,417 |
| 5 years | −1.02% | −10.18% | $990 |
| 10 years | +143.11% | +0.24% | $2,431 |
Over the last 6 months it has done better than 42% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Hang Seng: price only. Calculate your investment
The chart in detail
Sino Biopharmaceutical: technical analysis
Sino Biopharmaceutical is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 53.1% below its all-time closing high ($10.88, July 23, 2020).
- Trend
- Downward
- RSI (14 sessions)
- 41
- Between 30 and 70
- vs 200-session average
- −6.42%
Support and resistance
Price areas where Sino Biopharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$5.72+11.98%3 touches, last on November 9, 2026
- Resistance$5.51+7.86%4 touches, last on October 21, 2026
- Resistance$5.26+3.04%4 touches, last on September 14, 2026
- Last price$5.11
- Support$4.88−4.51%2 touches, last on July 17, 2026
- Support$4.74−7.23%5 touches, last on November 2, 2026
- Support$4.19−17.92%2 touches, last on June 29, 2026
Volatility and risk
Over the last year it has moved roughly in line with the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.13
- Volatility (60 sessions, annualised)
- 47.6%
- Largest fall in the last year
- −40.08%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Sino Biopharmaceutical: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Sino Biopharmaceutical has been February: +8.05% on average, positive in 17 years out of 26. The weakest has been September: −0.80% on average, positive in 10 years out of 26. November, the current month, has been positive in 11 years out of 26 (+5.62% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.55% | −0.22% | 10 of 26 |
| February | +8.05% | +8.33% | 17 of 26 |
| March | +3.79% | +1.00% | 13 of 26 |
| April | +4.22% | +0.48% | 13 of 26 |
| May | +2.88% | +4.15% | 16 of 26 |
| June | +1.02% | −0.68% | 8 of 26 |
| July | +5.40% | +2.90% | 15 of 26 |
| August | −0.37% | −0.90% | 11 of 26 |
| September | −0.80% | 0.00% | 10 of 26 |
| October | −0.43% | 0.00% | 13 of 27 |
| November | +5.62% | 0.00% | 11 of 26 |
| December | −0.41% | −0.86% | 8 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Sino Biopharmaceutical and its competitors
Based in Wan Chai, Hong Kong, and incorporated in 2000, Sino Biopharmaceutical Limited is an investment holding company whose operations centre on the research, development and sale of pharmaceuticals in the People's Republic of China. The group reports through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others.
- Headquarters
- Wan Chai, Hong Kong
- Employees
- 22,838
- Founded
- 2000
- Chief executive
- S. Y. Tse
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Sino Biopharmaceutical1177 | $11.65B | 28.2% | 34.2 | −1.26% |
| Pharmaron Beijing300759 | $10.59B | 14.0% | 39.3 | +44.36% |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | $12.15B | -0.2% | — | −8.83% |
| ALTEOGEN196170 | $9.05B | 47.2% | 97.1 | −36.93% |
| Haisco Pharmaceutical Group002653 | $8.97B | 21.1% | 44.1 | +0.54% |
| Genscript Biotech1548 | $8.77B | 14.9% | — | +112.07% |
Same industry or related industries, similar size. Compare Sino Biopharmaceutical with its competitors · Full profile
More on Sino Biopharmaceutical
- Sino Biopharmaceutical revenue and financials
- Sino Biopharmaceutical dividend and valuation
- Sino Biopharmaceutical stock return
- Sino Biopharmaceutical employees, headquarters and business
